Recently, PD-1/PD-L1 checkpoint-blockade strategies approved by the U.S. Food and Drug Administration (FDA) to promote anti-tumor immunities by inhibiting CTL exhaustion has demonstrated to be a promising cancer immunotherapy method with exciting clinical results in cancer treatment52. The gene discussed is CD274; the disease is neoplasm.